Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on Survival

被引:38
作者
Ishihara, Mikiya [1 ,4 ]
Mukai, Hirofumi [1 ]
Nagai, Shunji [1 ]
Onozawa, Masakatsu [2 ]
Nihei, Keiji [2 ]
Shimada, Toshiyuki [3 ]
Wada, Noriaki [3 ]
机构
[1] Natl Canc Ctr Hosp E, Div Hematol Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp E, Div Radiat Oncol, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp E, Div Breast Surg, Kashiwa, Chiba, Japan
[4] Mie Univ, Grad Sch Med, Dept Immunogene Therapy, Tsu, Mie 5148507, Japan
关键词
Breast cancer; Central nervous system; Ki67; Triple negative subtype; PROGNOSTIC-FACTORS; BRAIN METASTASES; CNS METASTASES; IMMUNOHISTOCHEMISTRY; METAANALYSIS; MALIGNANCY; CARCINOMA; MARKERS; KI-67;
D O I
10.1159/000345321
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Identifying factors that predispose patients to central nervous system (CNS) metastases may hasten disease detection and improve treatment outcomes. Methods: We reviewed the records of patients who were diagnosed with clinical stage I Ill primary breast cancer at the National Cancer Center Hospital East from 2003 to 2005. Cox proportional hazard models were fitted to reveal risk factors for CNS metastases. Results: The median follow-up period after the operation was 53.5 months. Among the 591 identified patients with breast cancer, 76 experienced a relapse. Seventeen patients developed CNS metastases. Multivariate analysis indicated that the triple negative (TN) subtype (hazard ratio = 5.5) and a high Ki67 labeling index (LI; hazard ratio = 3.9) were associated with a higher risk for CNS metastases. At 4 years, the TN subtype was associated with significantly worse overall and disease-free survival rates and a higher cumulative incidence of CNS metastases compared with hormone receptor-positive/ human epidermal growth factor receptor-2-negative tumors. Breast cancers with a Ki67 LI >= 30% were also associated with lower overall and disease-free survival rates and a higher cumulative incidence of CNS metastases compared with cancers with a Ki67 LI <30%. Conclusion: TN or Ki67-overexpressing breast cancer produced earlier CNS metastases and lower disease-free and overall survival rates. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:135 / 140
页数:6
相关论文
共 24 条
  • [1] Ki67 and cyclin A as prognostic factors in early breast cancer.: What are the optimal cut-off values?
    Ahlin, C.
    Aaltonen, K.
    Amini, R-M
    Nevanlinna, H.
    Fjallskog, M-L
    Blomqvist, C.
    [J]. HISTOPATHOLOGY, 2007, 51 (04) : 491 - 498
  • [2] Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis
    Altundag, Kadri
    Bondy, Melissa L.
    Mirza, Nadeern Q.
    Kau, Shu-Wan
    Broglio, Kristine
    Hortobagyi, Gabriel N.
    Rivera, Edgardo
    [J]. CANCER, 2007, 110 (12) : 2640 - 2647
  • [3] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
    Barnholtz-Sloan, JS
    Sloan, AE
    Davis, FG
    Vigneau, FD
    Lai, P
    Sawaya, RE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2865 - 2872
  • [4] Triple-negative breast cancer: therapeutic options
    Cleator, Susan
    Heller, Wolfgang
    Coombes, R. Charles
    [J]. LANCET ONCOLOGY, 2007, 8 (03) : 235 - 244
  • [5] Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
    Colozza, M
    Azambuja, E
    Cardoso, F
    Sotiriou, C
    Larsimont, D
    Piccart, MJ
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (11) : 1723 - 1739
  • [6] Survival among women with triple receptor-negative breast cancer and brain metastases
    Dawood, S.
    Broglio, K.
    Esteva, F. J.
    Yang, W.
    Kau, S. -W.
    Islam, R.
    Albarracin, C.
    Yu, T. K.
    Green, M.
    Hortobagyi, G. N.
    Gonzalez-Angulo, A. M.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (04) : 621 - 627
  • [7] Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    de Azambuja, E.
    Cardoso, F.
    de Castro, G., Jr.
    Colozza, M.
    Mano, M. S.
    Durbecq, V.
    Sotiriou, C.
    Larsimont, D.
    Piccart-Gebhart, M. J.
    Paesmans, M.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (10) : 1504 - 1513
  • [8] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
    Goldhirsch, A.
    Ingle, J. N.
    Gelber, R. D.
    Coates, A. S.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (08) : 1319 - 1329
  • [9] Heitz F, 2008, J CLIN ONCOL, V26
  • [10] Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index
    Jalava, P
    Kuopio, T
    Juntti-Patinen, L
    Kotkansalo, T
    Kronqvist, P
    Collan, Y
    [J]. HISTOPATHOLOGY, 2006, 48 (06) : 674 - 682